<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00005839</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000067854</org_study_id>
    <secondary_id>U01CA062505</secondary_id>
    <secondary_id>CHNMC-PHI-25</secondary_id>
    <secondary_id>CHNMC-IRB-99130</secondary_id>
    <secondary_id>NCI-T99-0005</secondary_id>
    <nct_id>NCT00005839</nct_id>
  </id_info>
  <brief_title>Oxaliplatin Plus Capecitabine in Treating Patients With Metastatic or Recurrent Solid Tumor</brief_title>
  <official_title>A Phase I Study of Oxaliplatin in Combination With Capecitabine in Metastatic/Recurrent Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>City of Hope Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>City of Hope Medical Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combining more than one drug may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of oxaliplatin combined with capecitabine&#xD;
      in treating patients who have metastatic or recurrent solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the maximum tolerated dose of capecitabine when administered in&#xD;
      combination with oxaliplatin in patients with metastatic or recurrent solid tumors. II.&#xD;
      Determine the toxicities of this treatment regimen in this patient population.&#xD;
&#xD;
      OUTLINE: This is a dose escalation study of capecitabine. Patients receive oxaliplatin IV&#xD;
      over 2 hours on day 1 and oral capecitabine twice daily on days 1-14. Treatment repeats every&#xD;
      2 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6&#xD;
      patients receive escalating doses of capecitabine until the maximum tolerated dose (MTD) is&#xD;
      determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience&#xD;
      dose limiting toxicity. Patients are followed for disease progression and survival.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 12-15 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2000</start_date>
  <completion_date type="Actual">June 2004</completion_date>
  <primary_completion_date type="Actual">June 2004</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically or cytologically confirmed metastatic or recurrent&#xD;
        solid tumor that has failed standard therapy or for which no standard therapy exists No&#xD;
        known brain metastases or carcinomatosis meningitis&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: SWOG 0-2 Karnofsky 60-100%&#xD;
        Life expectancy: At least 12 weeks Hematopoietic: WBC at least 3,000/mm3 Absolute&#xD;
        neutrophil count at least 1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin&#xD;
        no greater than 2 times normal AST no greater than 2.5 times normal Renal: Creatinine&#xD;
        normal OR Creatinine clearance greater than 60 mL/min Calcium no greater than 12 mg/dL&#xD;
        Cardiovascular: No symptomatic congestive heart failure No unstable angina pectoris No&#xD;
        cardiac arrhythmia Other: No evidence of neuropathy No history of allergies to platinum&#xD;
        compounds or antiemetics that would preclude study No other uncontrolled illness (e.g.,&#xD;
        ongoing or active infection) No medical, social, or psychological factors that would&#xD;
        preclude study Not pregnant or nursing Negative pregnancy test Fertile patients must use&#xD;
        effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 4 weeks since prior immunotherapy and&#xD;
        recovered Chemotherapy: At least 4 weeks since prior chemotherapy (6 weeks for mitomycin&#xD;
        and nitrosoureas) and recovered Prior fluorouracil or cisplatin allowed Endocrine therapy:&#xD;
        Not specified Radiotherapy: At least 4 weeks since prior radiotherapy and recovered&#xD;
        Surgery: Recovered from prior surgery Other: At least 30 days since prior investigational&#xD;
        drugs No concurrent antiretroviral therapy (HAART)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heinz-Josef Lenz, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Southern California</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>USC/Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033-0800</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beckman Research Institute, City of Hope</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Davis Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <study_first_submitted>June 2, 2000</study_first_submitted>
  <study_first_submitted_qc>April 18, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2003</study_first_posted>
  <last_update_submitted>June 3, 2015</last_update_submitted>
  <last_update_submitted_qc>June 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2015</last_update_posted>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

